Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension (STELLAR)
Source: View publication →
In the Phase 3 STELLAR trial, adding the first-in-class activin signaling inhibitor sotatercept to stable background therapy in patients with pulmonary arterial hypertension significantly improved exercise capacity and delayed clinical worsening compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
The STELLAR trial successfully demonstrated the efficacy of a novel mechanism of action in pulmonary arterial hypertension (PAH). Unlike standard therapies that act primarily as vasodilators via the prostacyclin, endothelin, or nitric oxide pathways, sotatercept targets the underlying pulmonary vascular remodeling by trapping activins and restoring anti-proliferative signaling. Its addition to background therapy yielded profound improvements in hemodynamics, exercise capacity, and clinical stability, establishing sotatercept as a transformative, first-in-class 'fourth pillar' of PAH management.
Historical Context
For over two decades, the therapeutic armamentarium for PAH has been limited to vasodilatory agents targeting the nitric oxide, endothelin, and prostacyclin pathways. Despite the use of upfront double or triple combination therapy, morbidity and mortality remained unacceptably high due to ongoing, irreversible proliferative remodeling of the pulmonary arterioles. Genetic and translational studies revealed that an imbalance favoring pro-proliferative activin signaling over anti-proliferative bone morphogenetic protein (BMP) signaling drives this remodeling. Sotatercept, originally developed for other indications, was repurposed as an activin ligand trap to restore this balance. Following the promising Phase 2 PULSAR trial, the Phase 3 STELLAR trial provided landmark evidence for this disease-modifying approach, ultimately leading to the FDA approval of sotatercept (Winrevair) in 2024 and shifting the paradigm of PAH treatment.
Guided Discussion
High-yield insights from every perspective
Sotatercept introduces a novel mechanism of action compared to traditional PAH therapies. How does its mechanism of inhibiting activin signaling fundamentally differ from the primary mechanisms of existing PAH classes like PDE-5 inhibitors or endothelin receptor antagonists?
Key Response
Traditional therapies primarily target endothelial dysfunction and promote vasodilation through the nitric oxide, endothelin, and prostacyclin pathways. Sotatercept acts as a ligand trap for the TGF-beta superfamily, specifically targeting activin signaling to restore the balance between pro-proliferative and anti-proliferative pathways, directly addressing the underlying pulmonary vascular remodeling rather than just altering vessel tone.
Given the results of the STELLAR trial, what are the most common adverse events you need to monitor for when starting a patient on sotatercept, and how might these influence your routine lab checks in clinic?
Key Response
Sotatercept was associated with increases in hemoglobin levels, thrombocytopenia, epistaxis, and telangiectasia. As a resident, it is critical to recognize the need for regular CBC monitoring to check for erythrocytosis or bleeding risks, which is distinct from the liver function or fluid status monitoring heavily emphasized with ERAs or prostacyclins.
The STELLAR trial included patients already on double or triple background PAH therapy. How do the improvements in pulmonary vascular resistance (PVR) seen with sotatercept in this heavily treated population challenge our previous understanding of the reversibility of pulmonary vascular remodeling in advanced PAH?
Key Response
Historically, severe PAH with high PVR on maximal medical therapy was thought to have fixed, irreversible vascular remodeling. The profound reductions in PVR seen with sotatercept in the STELLAR trial suggest that biological reverse remodeling is possible even in advanced disease stages, shifting the paradigm of PAH management from merely delaying progression to potentially reversing the disease process.
With sotatercept demonstrating both functional and hemodynamic improvements as an add-on therapy, how should this shift our long-term treatment algorithms for PAH, specifically regarding the timing of escalation to parenteral prostacyclins or lung transplantation?
Key Response
Sotatercept represents a shift towards disease-modifying therapy. Attendings must weigh whether to introduce sotatercept earlier in the disease course to prevent remodeling, or reserve it for those failing oral therapies before committing to the high morbidity of continuous parenteral prostacyclins or the finality of a lung transplant evaluation, introducing a critical new tier in the treatment algorithm.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The STELLAR trial utilized a fixed-sequence hierarchical testing strategy for its secondary endpoints, which included time to clinical worsening. What are the statistical advantages and limitations of using this testing method in a trial evaluating a novel disease-modifying agent in a rare disease like PAH?
Key Response
Hierarchical testing strongly controls the family-wise Type I error rate without needing alpha adjustment (like Bonferroni), maximizing power for early secondary endpoints. However, its limitation is that if an early endpoint in the hierarchy fails to reach significance, all subsequent endpoints are deemed exploratory, potentially leaving valuable clinical data formally unproven despite strong trends.
Given that sotatercept administration frequently causes noticeable hematologic changes such as increased hemoglobin and telangiectasias, how might functional unblinding have affected the subjective primary endpoint of 6-minute walk distance, and how should reviewers assess the trial's mitigation of this bias?
Key Response
Functional unblinding is a major threat to validity in placebo-controlled trials with distinct adverse effect profiles, especially when the primary endpoint relies on patient effort (6-minute walk test). A rigorous reviewer would scrutinize whether independent, blinded evaluators conducted the walk tests and whether robust improvements in objective measures (like PVR or NT-proBNP) sufficiently corroborate the subjective functional gains.
Current ESC/ERS guidelines emphasize initial combination therapy with endothelial-targeted drugs and reserve prostacyclins for high-risk patients. Based on the STELLAR data, what level of evidence does sotatercept achieve, and where exactly should it be inserted into the treatment algorithm for patients who remain intermediate-high risk on dual oral therapy?
Key Response
The STELLAR trial provides high-quality, randomized, placebo-controlled evidence (Level of Evidence A). The committee must decide if sotatercept should become a Class I recommendation for patients with inadequate response to initial double/triple therapy (WHO FC II-III), potentially positioning it ahead of or alongside parenteral prostacyclins for intermediate-high risk patients, representing a major structural update to the 2022 ESC/ERS guidelines.
Clinical Landscape
Noteworthy Related Trials
SERAPHIN Trial
Tested
Macitentan 3 mg or 10 mg daily
Population
Symptomatic pulmonary arterial hypertension patients
Comparator
Placebo
Endpoint
Time to first morbidity or mortality event
GRIPHON Trial
Tested
Selexipag up to 1600 mcg twice daily
Population
Patients with pulmonary arterial hypertension
Comparator
Placebo
Endpoint
Composite of death from any cause or a complication related to PAH
AMBITION Trial
Tested
Initial combination therapy with ambrisentan and tadalafil
Population
Treatment-naive patients with pulmonary arterial hypertension
Comparator
Monotherapy with ambrisentan or tadalafil
Endpoint
Time to first clinical failure event
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis